Announced
Financials
Tags
clinical research
Acquisition
Friendly
Private
United Kingdom
Pending
Majority
Single Bidder
Biotechnology
Cross Border
Private Equity
Synopsis
Behrman Capital-backed Emmes, a global, full-service Clinical Research Organization, agreed to acquire Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms were not disclosed. "We are thrilled with the addition of Orphan Reach to the Emmes platform, which we believe greatly augments the Company's BioPharma effort and builds on the recent and successful Neox transaction. Orphan Reach enhances Emmes' momentum and steepens the Company's growth trajectory through expansion of its geographic footprint and customer base, and we look forward to continuing to support the Company as it pursues organic initiatives and additional acquisitions," Grant Behrman, Behrman Capital Managing Partner.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.